Riik: Ameerika Ühendriigid
keel: inglise
Allikas: NLM (National Library of Medicine)
Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)
MWI
Erythromycin
Erythromycin 5 mg in 1 g
OPHTHALMIC
PRESCRIPTION DRUG
For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.
Sterile Erythromycin Ophthalmic Ointment USP, 0.5% is available as follows: 3.5 g (1/8 oz) sterile tamper-resistant tube (NDC 13985-605-03)
Abbreviated New Drug Application
ERYTHROMYCIN- ERYTHROMYCIN OINTMENT MWI ---------- APEXA™ ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% STERILE RX ONLY DESCRIPTION: Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3-_0_-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl- 7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D- xylo-hexo-pyranosyl]oxy]oxacyclotetradecane-2,10-dione)) is an antibiotic produced from a strain of _Streptomyces erythraeus._ It has the following structural formula: Molecular Formula: C H NO Molecular Weight: 733.94 Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum. CLINICAL PHARMACOLOGY: _MICROBIOLOGY:_ Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms _in vitro_ and in clinical infections: 37 67 13 _Streptococcus pyogenes_ (group A β-hemolytic) Alpha-hemolytic streptococci (viridans group) _Staphylococcus aureus,_ including penicillinase-producing strains (methicillin- resistant staphylococci are uniformly resistant to erythromycin) _Streptococcus pneumoniae_ _Mycoplasma pneumoniae_ (Eaton Agent, PPLO) INDICATIONS AND USAGE: For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to _N. gonorrhoeae_ or _C. trachomatis._ The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing _N.gonorrhoeae_ is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G sh Lugege kogu dokumenti